Last checked at 
(Adds details on background, competition)
Feb 24 (Reuters) - Canadian drugmaker Medicago said itreceived a contract from a U.S. federal agency to develop threedifferent potential treatments for Ebola.
The company said on Tuesday it would make the antibodies inits Quebec facility for a study in non-human primates.
Financial terms of the contract were not disclosed.
The Biomedical Advanced Research and Development Authority(BARDA) has told the company that its anti-Ebola treatmentsshould be efficient as Mapp Biopharmaceutical's ZMapp.
An outbreak of Ebola has killed close to 10,000 peopleacross West Africa over the last year. The number of new caseshas plummeted but officials have said much work still needs tobe done before the virus is snuffed out in Liberia, Guinea andSierra Leone, the three worst affected nations.
So far ZMapp and a compound from Tekmira PharmaceuticalsCorp have shown that their drugs could cure non-humanprimates given otherwise-lethal injections of Ebola virus.
Other companies that are currently testing potentialtreatments for the deadly infection are GlaxoSmithKline,Sarepta Pharmaceuticals Inc, Novavax Inc,Merck & Co, Johnson & Johnson and BioCrystPharmaceuticals Inc. (Reporting by Vidya L Nathan in Bengaluru; Editing by SaumyadebChakrabarty and Maju Samuel)
